Your browser doesn't support javascript.
loading
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.
Borse, Rebekah H; Brown, Chloe; Muszbek, Noemi; Chaudhary, Mohammad Ashraf; Kachroo, Sumesh.
Affiliation
  • Borse RH; Merck Research Laboratories (MRL), Merck & Co., Inc., Kenilworth, NJ, USA. rebekah.borse@merck.com.
  • Brown C; MSD Ltd, Hoddesdon, UK.
  • Muszbek N; Evidera, London, UK.
  • Chaudhary MA; Merck Research Laboratories (MRL), Merck & Co., Inc., Kenilworth, NJ, USA.
  • Kachroo S; Merck Research Laboratories (MRL), Merck & Co., Inc., Kenilworth, NJ, USA.
Rheumatol Ther ; 4(2): 427-443, 2017 Dec.
Article de En | MEDLINE | ID: mdl-28956301
INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime. The effectiveness outcome was quality-adjusted life-years (QALYs). Utilities were estimated by mapping Bath Ankylosing Spondylitis Functional Index scores, and the primary response measure was ≥50% improvement on the Bath Ankylosing Spondylitis Disease Activity Index at 12 weeks. Direct, medication, and AS management costs were included. Costs and outcomes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were comparable to each other and superior to conventional care. The incremental cost-effectiveness ratios (ICERs) for TNF-α inhibitors were £19,070-42,532 per QALY gained compared with conventional care. Analyses of the ICERs for each TNF-α inhibitor compared with conventional care demonstrated that golimumab was the most cost-effective treatment, and that adalimumab and etanercept were dominated by golimumab. Sensitivity analyses confirmed the robustness of these analyses. CONCLUSIONS: Golimumab may be considered a cost-effective treatment alternative for patients with active AS. With comparable costs and efficacy among TNF-α inhibitors, the choice of TNF-α inhibitor to treat AS is likely to be driven by patient and physician choice. FUNDING: Merck & Co., Inc.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Langue: En Journal: Rheumatol Ther Année: 2017 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Langue: En Journal: Rheumatol Ther Année: 2017 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni